Navigation Links
Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009
Date:8/24/2009

SOUTH SAN FRANCISCO, Calif., Aug. 24 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced two oral presentations at the European Society of Cardiology (ESC) Congress 2009 in Barcelona, Spain, that will feature its investigational antiplatelet drug elinogrel, a P2Y12 ADP receptor antagonist that is currently in Phase II clinical development with Novartis, Portola's development and commercialization partner.

Oral presentation details are as follows:

Title: First in Patient Experience with a New, Direct Acting, Reversible P2Y12 Inhibitor, Elinogrel (PRT060128): Evaluation in Patients with High Platelet Reactivity During Clopidogrel Therapy (Program #2678)

Presenter: Paul A. Gurbel, M.D., Director, Sinai Center for Thrombosis Research, Baltimore, Md.

Date: Monday, August 31, 4:45-5:00 p.m.

Location: Sofia Room, Zone 1

Title: The Clopidogrel-Insensitive Pool of P2Y12 Receptors Exposed Upon Platelet Activation Contributes to Thrombus Formation and Can Be Blocked by Elinogrel, a Direct Acting, Reversible P2Y12 Inhibitor (Program #5115)

Presenter: Helena Haberstock-Debic of Portola

Date: Wednesday, September 2, 11:15-11:30 a.m.

Location: Stockholm Room, Zone 4

About Elinogrel

Elinogrel is the only direct acting, reversible, i.v. and oral P2Y12 ADP receptor antagonist in clinical development. Inhibiting the P2Y12 ADP receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Because of its properties, elinogrel has the potential to provide significant clinical advantages compared to Plavix(R)* (clopidogrel), the current standard of care; newer agents, such as prasugrel; and those in development, by lowering the risk of ischemic events due to clot formation and reducing the risk of bleeding. In addition, elinogrel is the only compound in development that can be administered intravenously in the hospital and orally in the chronic setting.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease, inflammatory disease and cancer. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1B in upfront and milestone payments plus escalating double-digit royalties on future sales. Betrixaban, its oral Factor Xa inhibitor is licensed to Merck & Co., Inc., and elinogrel, its P2Y12 ADP receptor antagonist and potential competitor for Plavix* (clopidogrel), is licensed to Novartis. Both betrixaban and elinogrel are Phase II product candidates that have best-in-class features to address the global multi-billion hospital, specialty, and chronic care anticoagulant and antiplatelet markets, respectively.

Portola also has proprietary pipeline programs focused on the discovery and development of novel, specific Syk and JAK inhibitors to treat cancer and inflammatory diseases; a thromboxane receptor antagonist, which is an aspirin replacement product for patients intolerant to aspirin; and a novel anticoagulant antidote program with the potential to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit www.portola.com.

*Plavix(R) is a registered trademark of Sanofi/Aventis and Bristol Myers Squibb.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
3. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), reported today ... a total of 10,672,750 common share purchase warrants have been ... from the exercise of these warrants totalled $1,387,458 and 10,672,750 ... ... this expression of confidence by our warrant holders. This infusion ...
(Date:2/27/2017)... , February 27, 2017 ... Stock-Callers.com for evaluation today, and they are: Anthera Pharmaceuticals ... Biosciences of California Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals ... article on ETF Trends, market observers are growing more ... administration could enact reforms to free cash held overseas ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences ... Spain has been appointed as a Certified ... The IsoFlux system will be used in Genetracer Biotech,s ... to lung and colon cancer, with plans to move ... laboratory is utilizing Fluxion,s IsoFlux System to isolate, recover, ...
(Date:2/27/2017)... , ... February 27, 2017 , ... The Catalyst ... a few in the Midwest offering premix services and private label organic services. , ... laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, which owns the ...
Breaking Biology Technology:
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
Breaking Biology News(10 mins):